SHANGHAI, CHINA, Disamba 12, 2022 Wani kamfani mai zaman kansa kuma mai ƙirƙira na fasahar kere kere mai suna JW Therapeutics (HKEX: 2126) yana mai da hankali kan haɓakawa, ƙira, da siyar da samfuran rigakafin ƙwayoyin cuta. A taron shekara-shekara na 64th American Society of Hematology (ASH), kamfanin ya gabatar da sababbin bayanan asibiti game da Carteyva® (relmacabtagene autoleucel injection) a cikin manya na kasar Sin tare da relapsed / refractory follicular lymphoma (r / r FL) da kuma sake dawowa / refractory mantle cell lymphoma (r/r MCL).
Kuna so karanta: CAR T Cell far in China
Inganci da Tsaro na Relmacabtagene Autoleucel a cikin Manya tare da Rushewar Lymphoma mai Ragewa a China (lambar ƙira: 4640)
A cikin wannan muhimmin lokaci na II RELIANCE binciken, an haɗa marasa lafiya waɗanda suka tabbatar da digiri na 1, 2, ko 3a FL ta hanyar tarihi, tare da cutar r/r. An ba da izini ga marasa lafiya masu cancanta don karɓar relma-cel a matakin kashi na 100 × 106 ku 150×106 Kwayoyin CAR T, bin lymphodepletion chemotherapy. A yanke bayanan (Disamba 17, 2021), dangane da marasa lafiya 28 tare da watanni 11.7 na bin tsaka-tsaki, relma-cel ya nuna amsoshi na asibiti na ban mamaki, samun babban ƙimar ƙimar amsawa (CRR) da ƙimar amsa gabaɗaya (ORR) (6 watanni ORR, CRR sun kasance 100% da 83.33% bi da bi), da kuma bayanin martabar aminci mai kulawa (mai haƙuri 1 kawai ya sami Gr ≥3 neurotoxicity (NT), babu Gr ≥3 cytokine release syndrome (CRS)). Za a gabatar da bayanan aminci da inganci tare da dogon bibiya.
Kuna so karanta: Farashin CAR T Cell a China
Tsaro na Farko da Ingantaccen Relmacabtagene Autoleucel (relma-cel) a cikin Manya marasa lafiya tare da Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) a China (lambar ƙima: 3326)
Mutanen da ke da MCL da suka shiga cikin wannan binciken budaddiyar lakabin hannu guda na II a kasar Sin sun sami akalla nau'ikan magani guda biyu, irin su anti-CD20 antibodies, anthracycline ko bendamustine, da BTKis. Bayan lymphodepleting chemotherapy, mahalarta sun karbi relma-cel (100 × 106 CAR + T Kwayoyin). Tun daga ranar 30 ga Nuwamba, 2021, bayanan farko dangane da marasa lafiya 11 sun ba da kyakkyawan sakamako na ingancin asibiti (mafi kyawun ORR 81.8%, mafi kyawun CRR 54.5%) a cikin marasa lafiya masu haɗari tare da r/r MCL da ƙarancin ƙarancin sa ≥ 3 CRS (1) haƙuri) da kuma rigakafi mai tasiri na ƙwayoyin cuta neurotoxicity syndrome (ICANS, 1 haƙuri). Wannan binciken yana gudana, kuma za a gabatar da ƙarin sakamako.
Game da allurar Relmacabtagene Autoleucel (sunan kasuwanci: Carteyva®)
Relmacabtagene autoleucel allura (wanda aka rage shi da relma-cel, sunan kasuwanci: Carteyva®) shi ne autologous anti-CD19 CAR-T cell immunotherapy samfurin da kansa ya haɓaka ta hanyar JW Therapeutics bisa a CAR-T cell Tsarin tsari na Juno Therapeutics (kamfanin Bristol Myers Squibb). Kasancewa samfurin farko na JW Therapeutics, relma-cel ta sami amincewar Hukumar Kula da Kayayyakin Kiwon Lafiya ta kasar Sin (NMPA) don alamu guda biyu, gami da kula da manya marasa lafiya tare da babban ƙwayar lymphoma B-cell da suka koma baya ko kuma suna jujjuyawa bayan layi biyu ko fiye na tsarin tsarin. jiyya, da kuma kula da tsofaffi marasa lafiya tare da lymphoma follicular wanda ke da wuyar gaske ko kuma ya sake dawowa a cikin watanni 24 na layi na biyu ko sama da tsarin tsarin (r / r FL), yana mai da shi na farko. CAR-T samfurin an amince da shi azaman samfuri na nau'in halitta na 1 a China. A halin yanzu, shi ne kawai CAR-T samfurin a China wanda aka haɗa a lokaci guda a cikin Sabon Muhimmancin Sabon Shirin Ci gaban Magunguna na Ƙasa, bita na fifiko, da kuma naɗin jiyya.
Kuna so karanta: CAR T Cell far don Multi myeloma a China
Game da JW Therapeutics
JW Therapeutics (HKEX: 2126) kamfani ne mai zaman kansa kuma ƙwararren ƙwararren masanin ilimin halittu wanda ke mai da hankali kan haɓakawa, masana'antu, da kasuwancin samfuran rigakafin ƙwayoyin cuta, kuma ya himmatu wajen zama jagorar ƙididdigewa a cikin rigakafin ƙwayoyin cuta. An kafa shi a cikin 2016, JW Therapeutics ya gina dandamali na duniya don haɓaka samfura a cikin ƙwayoyin rigakafi, da kuma bututun samfurin da ke rufe cututtukan cututtukan jini, ciwace-ciwacen ciwace-ciwace, da cututtukan autoimmune. JW Therapeutics ya himmatu wajen kawo ci gaba da ingantattun samfuran rigakafin rigakafin ƙwayoyin cuta da fatan samun waraka ga marasa lafiya a kasar Sin da ma duniya baki daya, da kuma jagorantar ingantacciyar ci gaban masana'antar rigakafin ƙwayoyin cuta ta Sinawa.
